Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411080 | 1.00 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2TLR2 | |
| SCHEMBL30411002 | 0.84 | TLR2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2TLR2 | |
| SCHEMBL30410806 | 0.84 | TLR2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2TLR2 | |
| SCHEMBL30410385 | 0.84 | TLR2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2TLR2 | |
| SCHEMBL30411340 | 0.84 | TLR2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2TLR2 | |
| SCHEMBL30411536 | 0.84 | TLR2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2TLR2 | |
| SCHEMBL29386513 | 0.82 | TLR2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2TLR2 | |
| SCHEMBL28950788 | 0.80 | L3MBTL1 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2TLR2 | |
| SCHEMBL12192745 | 0.77 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2HDAC3 | |
| SCHEMBL30159008 | 0.77 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | SMYD2 581/4885CYP3A4 3493/4885HTT 3084/4885 |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | SMYD2 581/4885CYP3A4 3493/4885HTT 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.